Literature DB >> 2902139

Characterization of lymphoid tumors induced by a recombinant murine retrovirus carrying the avian v-myc oncogene. Identification of novel (B-lymphoid) tumors in the thymus.

B K Brightman1, K G Chandy, R H Spencer, S Gupta, P K Pattengale, H Fan.   

Abstract

Lymphoid tumors induced by a recombinant murine retrovirus carrying the v-myc oncogene of avian MC29 virus were characterized. The Moloney murine leukemia virus myc oncogene (M-MuLV (myc], carried by an amphotropic MuLV helper, induced tumors in NIH Swiss and NFS/N mice after a relatively long latency (8 to 24 wk). Tumor masses appeared in the thymus, spleen, and lymph nodes. Flow cytometry of the tumor cells indicated that approximately 50% were positive for Thy 1.2. Most of these tumors also expressed one or more other cell surface markers of thymocytes and mature T cells (CD4, CD8). Southern blot hybridization revealed genomic rearrangements for the TCR beta genes. The TCR beta analysis suggested that the M-MuLV(myc)-induced Thy 1.2+ tumors were derived from somewhat less mature cells than tumors induced by M-MuLV, which is a classical non-acute retrovirus lacking an oncogene. The remainder of the M-MuLV(myc)-induced tumors were Thy 1.2-, but they were positive for Ly-5 (B220) and also for MAC-2. The Thy 1.2- tumors were characteristically located in the thymus. However, they were negative for TCR beta gene rearrangements. Some, but not all, of the Thy 1.2- tumors contained rearrangements for Ig genes. Additionally, they typically expressed mRNA specific for B but not for T cells. Thus, these thymic tumors had characteristics of the B cell lineage. Tumor transplantation experiments demonstrated that the Thy 1.2- tumor cells could reestablish in the thymus and spleen of irradiated hosts, and low level expression of the Thy 1 molecule was observed in the thymus but not the spleen on the first passage. After serial passage, one Thy 1- tumor altered its cell surface phenotype to Thy 1low B220-.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902139

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.

Authors:  Karen Rulli; Jack Lenz; Laura S Levy
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Bone marrow depletion by 89Sr complements a preleukemic defect in a long terminal repeat variant of Moloney murine leukemia virus.

Authors:  Q X Li; H Fan
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Proviral activation of the c-myb proto-oncogene is detectable in preleukemic mice infected neonatally with Moloney murine leukemia virus but not in resulting end stage T lymphomas.

Authors:  B Belli; L Wolff; V Nazarov; H Fan
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

4.  Tandemization of a subregion of the enhancer sequences from SRS 19-6 murine leukemia virus associated with T-lymphoid but not other leukemias.

Authors:  S W Granger; L M Bundy; H Fan
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  The helper virus envelope glycoprotein affects the disease specificity of a recombinant murine leukemia virus carrying a v-myc oncogene.

Authors:  S W Granger; H Fan
Journal:  Virus Genes       Date:  2001-06       Impact factor: 2.332

6.  Tumorigenic potential of a recombinant retrovirus containing sequences from Moloney murine leukemia virus and feline leukemia virus.

Authors:  C R Starkey; P A Lobelle-Rich; S W Granger; S Granger; B K Brightman; H Fan; L S Levy
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

Review 7.  Hematopoietic stem cells and retroviral infection.

Authors:  Prabal Banerjee; Lindsey Crawford; Elizabeth Samuelson; Gerold Feuer
Journal:  Retrovirology       Date:  2010-02-04       Impact factor: 4.602

8.  Escape from in vivo restriction of Moloney mink cell focus-inducing viruses driven by the Mo+PyF101 long terminal repeat (LTR) by LTR alterations.

Authors:  B K Brightman; C Farmer; H Fan
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

9.  BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.

Authors:  S S Clark; E Chen; M Fizzotti; O N Witte; V Malkovska
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

10.  Deletion of a GC-rich region flanking the enhancer element within the long terminal repeat sequences alters the disease specificity of Moloney murine leukemia virus.

Authors:  R Hanecak; P K Pattengale; H Fan
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.